"The Saint John's Cancer Institute at Providence Saint John’s Health Center is a cancer research institute dedicated to the understanding and curing of cancer. Our mission is accomplished through innovative clinical and laboratory research and the education of the next generation of surgical oncologists and scientists."

During the past decade, John Wayne Cancer Institute conducted 50 clinical trials. In the 10-year time frame, 50 clinical trials started and 11 clinical trials were completed, i.e. on average, 22% percent of trials that started reached the finish line to date. In the past 5 years, 22 clinical trials started and 10 clinical trials were completed. i.e. 45.5% of trials that started reached the finish line.

Out of the total clinical trials conducted in "John Wayne Cancer Institute" #1 sponsor was "Saint John's Cancer Institute" with 8 trials, followed by "Alliance for Clinical Trials in Oncology" with 5 trials sponsored, "Incyte Corporation" with 3 trials sponsored, "Viralytics" with 3 trials sponsored and "Blue Earth Diagnostics" with 3 trials sponsored. Other sponsors include 55 different institutions and companies that sponsored additional 60 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "John Wayne Cancer Institute" #1 collaborator was "National Cancer Institute (NCI)" with 13 trials as a collaborator, "Merck Sharp & Dohme LLC" with 3 trials as a collaborator, "Eli Lilly and Company" with 2 trials as a collaborator, "Parexel" with 2 trials as a collaborator and "Regeneron Pharmaceuticals" with 2 trials as a collaborator. Other collaborators include 27 different institutions and companies that were collaborators in the rest 35 trials.

According to Clinical.Site data, the most researched conditions in "John Wayne Cancer Institute" are "Melanoma" (15 trials), "Breast Cancer" (7 trials), "Melanoma (Skin)" (6 trials), "Glioblastoma" (3 trials) and "Invasive Breast Carcinoma" (3 trials). Many other conditions were trialed in "John Wayne Cancer Institute" in a lesser frequency.

Most popular intervention types in "John Wayne Cancer Institute" are "Drug" (48 trials), "Biological" (23 trials), "Procedure" (12 trials), "Other" (10 trials) and "Device" (6 trials). Other intervention types were less common.

The name of intervention was led by "Pembrolizumab" (5 trials), "Ipilimumab" (4 trials), "Nivolumab" (4 trials), "Questionnaire Administration" (4 trials) and "Quality-of-Life Assessment" (3 trials). Other intervention names were less common.

The vast majority of trials in "John Wayne Cancer Institute" are 68 trials for "All" genders, 9 trials for "Female" genders and 4 trials for "Male" genders.

Currently, there are NaN active trials in "John Wayne Cancer Institute". undefined are not yet recruiting, 13 are recruiting, 7 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 37 completed trials in John Wayne Cancer Institute, 3 suspended trials, and 9 terminated clinical trials to date.

Out of the total trials that were conducted in John Wayne Cancer Institute, 15 "Phase 1" clinical trials were conducted, 31 "Phase 2" clinical trials and 26 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 5 trials that are defined as “Not Applicable".